Sejal Shah, Molly L Tanenbaum, Alondra Loyola, Nathan Grant L Sala, Himani Darji, Sarah Hanes, Franziska K Bishop, Korey K Hood, David M Maahs
{"title":"连续血糖监测仪在公共保险青少年2型糖尿病患者中的应用：为期12个月的试点和可行性研究","authors":"Sejal Shah, Molly L Tanenbaum, Alondra Loyola, Nathan Grant L Sala, Himani Darji, Sarah Hanes, Franziska K Bishop, Korey K Hood, David M Maahs","doi":"10.1177/19322968251368366","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes (T2D) disproportionately affects youth with public insurance of minority and lower socioeconomic status backgrounds. We aimed to determine feasibility of CGM use in this understudied population.</p><p><strong>Methods: </strong>We enrolled youth <20 years old with T2D, provided or prescribed intermittent scanned CGM, and followed established clinic workflows with six data collection visits over 12-months. CGM use was measured by % wear time per two-week period (>75% wear-time as goal) from downloaded report prior to clinic visit. Exploratory outcomes included: 14-day CGM wear time in range (TIR: % time spent between 70 and 180 mg/dl), HbA1c, and patient-reported outcomes (PROs) collected from youth and parents.</p><p><strong>Results: </strong>We enrolled 30 youth (age 15.1 years [SD 2.48]; HbA1c 10.2%, range: 6.5%-15.5%), 46.7% female, 90% Hispanic. At baseline, 37% previously used CGM and 53% lacked glucometer data. CGM use was 50% at three months and 23% at 12 months. CGM wear time decreased by 6.4 days per two weeks by 12 months. Mean HbA1c was 9.8% at 12 months and median TIR decreased from 71% to 42%. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life.</p><p><strong>Conclusions: </strong>Strategies for sustained CGM use in youth with T2D may differ from adults with T2D or youth with type 1 diabetes. Additional studies are needed to evaluate facilitators and barriers of sustained CGM use to optimize CGM use in youth with T2D.</p><p><strong>Clinicaltrials: </strong>gov registration:NCT05074667.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968251368366"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450209/pdf/","citationCount":"0","resultStr":"{\"title\":\"Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.\",\"authors\":\"Sejal Shah, Molly L Tanenbaum, Alondra Loyola, Nathan Grant L Sala, Himani Darji, Sarah Hanes, Franziska K Bishop, Korey K Hood, David M Maahs\",\"doi\":\"10.1177/19322968251368366\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Type 2 diabetes (T2D) disproportionately affects youth with public insurance of minority and lower socioeconomic status backgrounds. We aimed to determine feasibility of CGM use in this understudied population.</p><p><strong>Methods: </strong>We enrolled youth <20 years old with T2D, provided or prescribed intermittent scanned CGM, and followed established clinic workflows with six data collection visits over 12-months. CGM use was measured by % wear time per two-week period (>75% wear-time as goal) from downloaded report prior to clinic visit. Exploratory outcomes included: 14-day CGM wear time in range (TIR: % time spent between 70 and 180 mg/dl), HbA1c, and patient-reported outcomes (PROs) collected from youth and parents.</p><p><strong>Results: </strong>We enrolled 30 youth (age 15.1 years [SD 2.48]; HbA1c 10.2%, range: 6.5%-15.5%), 46.7% female, 90% Hispanic. At baseline, 37% previously used CGM and 53% lacked glucometer data. CGM use was 50% at three months and 23% at 12 months. CGM wear time decreased by 6.4 days per two weeks by 12 months. Mean HbA1c was 9.8% at 12 months and median TIR decreased from 71% to 42%. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life.</p><p><strong>Conclusions: </strong>Strategies for sustained CGM use in youth with T2D may differ from adults with T2D or youth with type 1 diabetes. Additional studies are needed to evaluate facilitators and barriers of sustained CGM use to optimize CGM use in youth with T2D.</p><p><strong>Clinicaltrials: </strong>gov registration:NCT05074667.</p>\",\"PeriodicalId\":15475,\"journal\":{\"name\":\"Journal of Diabetes Science and Technology\",\"volume\":\" \",\"pages\":\"19322968251368366\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450209/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes Science and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/19322968251368366\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968251368366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.
Background: Type 2 diabetes (T2D) disproportionately affects youth with public insurance of minority and lower socioeconomic status backgrounds. We aimed to determine feasibility of CGM use in this understudied population.
Methods: We enrolled youth <20 years old with T2D, provided or prescribed intermittent scanned CGM, and followed established clinic workflows with six data collection visits over 12-months. CGM use was measured by % wear time per two-week period (>75% wear-time as goal) from downloaded report prior to clinic visit. Exploratory outcomes included: 14-day CGM wear time in range (TIR: % time spent between 70 and 180 mg/dl), HbA1c, and patient-reported outcomes (PROs) collected from youth and parents.
Results: We enrolled 30 youth (age 15.1 years [SD 2.48]; HbA1c 10.2%, range: 6.5%-15.5%), 46.7% female, 90% Hispanic. At baseline, 37% previously used CGM and 53% lacked glucometer data. CGM use was 50% at three months and 23% at 12 months. CGM wear time decreased by 6.4 days per two weeks by 12 months. Mean HbA1c was 9.8% at 12 months and median TIR decreased from 71% to 42%. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life.
Conclusions: Strategies for sustained CGM use in youth with T2D may differ from adults with T2D or youth with type 1 diabetes. Additional studies are needed to evaluate facilitators and barriers of sustained CGM use to optimize CGM use in youth with T2D.
期刊介绍：
The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
